CN Patent

CN101778840B — ((1s)-1-(((2s)-2-(5-(4’-(2-((2s)-1-((2s)-2-((甲氧羰基)氨基)-3-甲基丁酰基)-2-吡咯烷基)-1h-咪唑-5-基)-4-联苯基)-1h-咪唑-2-基)-1-吡咯烷基)羰基)-2-甲基丙基)氨基甲酸甲酯二盐酸盐的晶型

Assigned to Bristol Myers Squibb Co · Expires 2013-11-13 · 13y expired

What this patent protects

本发明一般性地涉及((1S)-1-(((2S)-2-(5-(4’-(2-((2S)-1-((2S)-2-((甲氧羰基)氨基)-3-甲基丁酰基)-2-吡咯烷基)-1H-咪唑-5-基)-4-联苯基)-1H-咪唑-2-基)-1-吡咯烷基)羰基)-2-甲基丙基)氨基甲酸甲酯二盐酸盐的晶型。本发明的公开内容一般性地还涉及包括晶型的药物组合物，以及使用该晶型治疗丙型肝炎的方法以及获得这种晶型的方法。

USPTO Abstract

本发明一般性地涉及((1S)-1-(((2S)-2-(5-(4’-(2-((2S)-1-((2S)-2-((甲氧羰基)氨基)-3-甲基丁酰基)-2-吡咯烷基)-1H-咪唑-5-基)-4-联苯基)-1H-咪唑-2-基)-1-吡咯烷基)羰基)-2-甲基丙基)氨基甲酸甲酯二盐酸盐的晶型。本发明的公开内容一般性地还涉及包括晶型的药物组合物，以及使用该晶型治疗丙型肝炎的方法以及获得这种晶型的方法。

Drugs covered by this patent

daclatasvir-dihydrochloride (DACLATASVIR DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN101778840B
Jurisdiction: CN
Classification: —
Expires: 2013-11-13
Drug substance claim: No
Drug product claim: No
Assignee: Bristol Myers Squibb Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.